Effect of Arogyavardhini vati herbal drug in the fatty Liver Disease
Phase 4
- Conditions
- Health Condition 1: null- Fatty Liver Disease
- Registration Number
- CTRI/2014/12/005262
- Lead Sponsor
- Dr Dasi Padmaja
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 200
Inclusion Criteria
1. Patients of both sexes between the aged
group of 20-50 yrs.
2. Abnormal liver function test positive for Alanine transamise Test and AST.
3. After hematological investigations of lipid profile.
4. Clinically and Ultrasonography evidence of fatty liver disease.
Exclusion Criteria
1. Infectious conditions.
2. Cirrhosis of liver.
3. Hepatitis B & C.
4. Ascites.
5. Obstructive pathologies.
6. Pregnant women/lactating women.
7. Tuberculosis .
8. Malignancies.
9. Immunodeficiency diseases
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Relief in signs and symptoms number of patients <br/ ><br>with sustained reduction in abnormal liver <br/ ><br>function tests to 50% of baseline. <br/ ><br>Timepoint: Relief in signs and symptoms number of patients <br/ ><br>with sustained reduction in abnormal liver <br/ ><br>function tests to 50% of baseline. <br/ ><br>
- Secondary Outcome Measures
Name Time Method me Outcome Timepoints <br/ ><br>Change in abnormal lipid profile and fatty Liver <br/ ><br>through ultrasonography. <br/ ><br>Change in Body Mass Index.Timepoint: Treatment period :60 days <br/ ><br>Assessment :For every 15 days <br/ ><br>Active follow up :3months <br/ ><br>